DS
SYRS

David Shaw’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

David Shaw’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,181
Closed -$145K – 5860
2022
Q1 		$145K Buy
+12,181
New +$218K ﹤0.01% 4942
2021
Q2 		– Sell
-3,768
Closed -$282K – 5075
2021
Q1 		$282K Sell
3,768
-19,601
-84% -$2.04M ﹤0.01% 3736
2020
Q4 		$2.54M Buy
23,369
+4,251
+22% +$388K ﹤0.01% 2403
2020
Q3 		$1.69M Sell
19,118
-4,125
-18% -$469K ﹤0.01% 2513
2020
Q2 		$2.48M Buy
23,243
+14,761
+174% +$1.32M ﹤0.01% 2237
2020
Q1 		$503K Sell
8,482
-6,226
-42% -$422K ﹤0.01% 3205
2019
Q4 		$1.02M Buy
14,708
+7,414
+102% +$450K ﹤0.01% 2980
2019
Q3 		$757K Sell
7,294
-2,139
-23% -$202K ﹤0.01% 2986
2019
Q2 		$873K Sell
9,433
-1,836
-16% -$128K ﹤0.01% 2758
2019
Q1 		$1.03M Buy
11,269
+2,381
+27% +$166K ﹤0.01% 2595
2018
Q4 		$496K Buy
8,888
+7,859
+764% +$597K ﹤0.01% 3093
2018
Q3 		$123K Buy
+1,029
New +$119K ﹤0.01% 3606

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

David Shaw's SYRS Position: Q2 2022 in Review

David Shaw sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 12,181 shares — an estimated $145K sold.

David Shaw first reported a position in SYRS in Q3 2018 and held it in 12 quarters. The position peaked at $2.54M in Q4 2020. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

  • David Shaw reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • David Shaw sold 12,181 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $145K.
  • David Shaw first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 12 quarters.
  • David Shaw's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.54M in Q4 2020.
  • 67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.